Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of C21 on Forearm Blood Flow in Healthy Males
NCT05277922Phase 1Completed
- Sponsor
- Vicore Pharma
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of buloxibutid in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Vicore Pharma. Primary endpoint: Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intraarterial Doses of C21 at 85 minutes. Started Apr 2022; status: completed.
02
Drugs
buloxibutid
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05277922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277922.